Percutaneous coronary intervention versus optimal medical therapy for prevention of spontaneous myocardial infarction in subjects with stable ischemic heart disease

Circulation

Volumn 127, Issue 7, 2013, Pages 769-781

  Bangalore, Sripal ^a   Pursnani, Seema ^b   Kumar, Sunil ^c   Bagos, Pantelis G ^d  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^c UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

^d UNIVERSITY OF CENTRAL GREECE   (Greece)

Author keywords

optimal medical therapy; periprocedural myocardial infarction

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LISINOPRIL; LOSARTAN; METOPROLOL; MOLSIDOMINE; NICOTINIC ACID; NITRATE; SIMVASTATIN;

ARTICLE; CARDIOVASCULAR MORTALITY; COCHRANE LIBRARY; EMBASE; FATALITY; FOLLOW UP; HEART INFARCTION; HUMAN; HYPERTENSION; INCIDENT RATE RATIO; ISCHEMIC HEART DISEASE; MEDLINE; META ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SYSTEMATIC REVIEW;

ANGIOPLASTY, BALLOON, CORONARY; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 84874115576     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.112.131961     Document Type: Article

References (49)

1. Prasad A, Gersh BJ, Bertrand ME, Lincoff AM, Moses JW, Ohman EM, White HD, Pocock SJ, McLaurin BT, Cox DA, Lansky AJ, Mehran R, Stone GW. Prognostic significance of periprocedural versus spontaneously occurring myocardial infarction after percutaneous coronary intervention in patients with acute coronary syndromes: an analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. J Am Coll Cardiol. 2009;54:477-486.
2. Park DW, Kim Y, Park G, Hwang K, Kwon C, Jang J, Choi S, Song S, Ahn J, Kim W, Lee J, Kang S, Lee S, Kim Y, Lee C, Park S, Park S. Incidence, mechanisms, predictors, and clinical significance of periprocedural myocardial infarction following percutaneous coronary intervention: comprehensive analysis of individual data from 11 PCI clinical studies Circulation.2011;124:A15146.
3. Damman P, Wallentin L, Fox KA, Windhausen F, Hirsch A, Clayton T, Pocock SJ, Lagerqvist B, Tijssen JG, de Winter RJ. Long-term cardiovascular mortality after procedure-related or spontaneous myocardial infarction in patients with non-ST-segment elevation acute coronary syndrome: a collaborative analysis of individual patient data from the FRISC II, ICTUS, and RITA-3 trials (FIR). Circulation. 2012;125:568-576.
4. Kini AS, Lee P, Marmur JD, Agarwal A, Duffy ME, Kim MC, Sharma SK. Correlation of postpercutaneous coronary intervention creatine kinase-MB and troponin I elevation in predicting mid-term mortality. Am J Cardiol. 2004;93:18-23. (Pubitemid 38022028)
5. Natarajan MK, Kreatsoulas C, Velianou JL, Mehta SR, Pericak D, Goodhart DM. Incidence, predictors, and clinical significance of troponin-I elevation without creatine kinase elevation following percutaneous coronary interventions. Am J Cardiol. 2004;93:750-753. (Pubitemid 38338569)
6. Pervaiz MH, Sood P, Sudhir K, Hermiller JB, Hou L, Hattori K, Su X, Cao S, Wang J, Applegate RJ, Kereiakes DJ, Yaqub M, Stone GW, Cutlip DE. Periprocedural myocardial infarction in a randomized trial of everolimuseluting and paclitaxel-eluting coronary stents: frequency and impact on mortality according to historic versus universal definitions. Circ Cardiovasc Interv. 2012;5:150-156.
7. Califf RM, Abdelmeguid AE, Kuntz RE, Popma JJ, Davidson CJ, Cohen EA, Kleiman NS, Mahaffey KW, Topol EJ, Pepine CJ, Lipicky RJ, Granger CB, Harrington RA, Tardiff BE, Crenshaw BS, Bauman RP, Zuckerman BD, Chaitman BR, Bittl JA, Ohman EM. Myonecrosis after revascularization procedures. J Am Coll Cardiol. 1998;31:241-251. (Pubitemid 28153440)
8. Brener SJ, Lytle BW, Schneider JP, Ellis SG, Topol EJ. Association between CK-MB elevation after percutaneous or surgical revascularization and three-year mortality. J Am Coll Cardiol. 2002;40:1961-1967. (Pubitemid 35428831)
9. Novack V, Pencina M, Cohen DJ, Kleiman NS, Yen CH, Saucedo JF, Berger PB, Cutlip DE. Troponin criteria for myocardial infarction after percutaneous coronary intervention. Arch Intern Med. 2012;172:502-508.
10. Higgins JPT, Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration2011. http://www.cochrane-handbook.org. Accessed February 4, 2013.
11. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement: Quality of Reporting of Meta-analyses. Lancet. 1999;354:1896-1900.
12. Bradburn MJ, Deeks JJ, Altman DG. Sbe24: Metan: an alternative metaanalysis command. Stata Tech Bull Reprints. 1998;8:86-100.
13. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188. (Pubitemid 17189972)
14. Galbraith RF. A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med. 1988;7:889-894.
15. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ. 2003;326:219. (Pubitemid 36143396)
16. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-634. (Pubitemid 27387172)
17. Bagos P, Nikolopoulos G. Mixed-effects poisson regression models for meta-analysis of follow-up studies with constant or varying durations. Int J Biostat. 2009;5:1-33.
18. Higgins JP, Thompson SG. Controlling the risk of spurious findings from meta-regression. Stat Med. 2004;23:1663-1682. (Pubitemid 38765338)
19. RITA-2 Trial Participants. Coronary angioplasty versus medical therapy for angina: the Second Randomised Intervention Treatment of Angina (RITA-2) trial. Lancet. 1997;350:461-468.
20. Bech GJ, De Bruyne B, Pijls NH, de Muinck ED, Hoorntje JC, Escaned J, Stella PR, Boersma E, Bartunek J, Koolen JJ, Wijns W. Fractional flow reserve to determine the appropriateness of angioplasty in moderate coronary stenosis: a randomized trial. Circulation. 2001;103:2928-2934. (Pubitemid 32578130)
21. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GB, Weintraub WS; COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503-1516. (Pubitemid 46588415)
22. Erne P, Schoenenberger AW, Burckhardt D, Zuber M, Kiowski W, Buser PT, Dubach P, Resink TJ, Pfisterer M. Effects of percutaneous coronary interventions in silent ischemia after myocardial infarction: the SWISSI II randomized controlled trial. JAMA. 2007;297:1985-1991. (Pubitemid 46740350)
23. Folland ED, Hartigan PM, Parisi AF; Veterans Affairs ACME Investigators. Percutaneous transluminal coronary angioplasty versus medical therapy for stable angina pectoris: outcomes for patients with double-vessel versus single-vessel coronary artery disease in a Veterans Affairs cooperative randomized trial. J Am Coll Cardiol. 1997;29:1505-1511. (Pubitemid 27272443)
24. Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, MacGregor JM, Orchard TJ, Chaitman BR, Genuth SM, Goldberg SH, Hlatky MA, Jones TL, Molitch ME, Nesto RW, Sako EY, Sobel BE. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360:2503-2515.
25. Hartigan PM, Giacomini JC, Folland ED, Parisi AF; Veterans Affairs Cooperative Studies Program ACME Investigators: Angioplasty Compared to Medicine. Two-to three-year follow-up of patients with single-vessel coronary artery disease randomized to PTCA or medical therapy (results of a VA cooperative study). Am J Cardiol. 1998;82:1445-1450. (Pubitemid 29006464)
26. Henderson RA, Pocock SJ, Clayton TC, Knight R, Fox KA, Julian DG, Chamberlain DA; Second Randomized Intervention Treatment of Angina (RITA-2) Trial Participants. Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy. J Am Coll Cardiol. 2003;42:1161-1170. (Pubitemid 37188334)
27. Hueb W, Lopes NH, Gersh BJ, Soares P, Machado LA, Jatene FB, Oliveira SA, Ramires JA. Five-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation. 2007;115:1082-1089. (Pubitemid 46673170)
28. Hueb W, Soares PR, Gersh BJ, César LA, Luz PL, Puig LB, Martinez EM, Oliveira SA, Ramires JA. The Medicine, Angioplasty, or Surgery Study (MASS-II): a randomized, controlled clinical trial of three therapeutic strategies for multivessel coronary artery disease: one-year results. J Am Coll Cardiol. 2004;43:1743-1751. (Pubitemid 38622508)
29. Hueb WA, Bellotti G, de Oliveira SA, Arie S, de Albuquerque CP, Jatene AD, Pileggi F. The Medicine, Angioplasty or Surgery Study (MASS): a prospective, randomized trial of medical therapy, balloon angioplasty or bypass surgery for single proximal left anterior descending artery stenoses. J Am Coll Cardiol. 1995;26:1600-1605.
30. Hueb WA, Soares PR, Almeida De Oliveira S, Ariê S, Cardoso RH, Wajsbrot DB, Cesar LA, Jatene AD, Ramires JA. Five-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS): a prospective, randomized trial of medical therapy, balloon angioplasty, or bypass surgery for single proximal left anterior descending coronary artery stenosis. Circulation. 1999;100(suppl 19):II107-II113. (Pubitemid 29523518)
31. Nishigaki K, Yamazaki T, Kitabatake A, Yamaguchi T, Kanmatsuse K, Kodama I, Takekoshi N, Tomoike H, Hori M, Matsuzaki M, Takeshita A, Shimbo T, Fujiwara H; Japanese Stable Angina Pectoris Study Investigators. Percutaneous coronary intervention plus medical therapy reduces the incidence of acute coronary syndrome more effectively than initial medical therapy only among patients with low-risk coronary artery disease: a randomized, comparative, multicenter study. J Am Coll Cardiol Cardiovasc Interv. 2008;1:469-479.
32. Parisi AF, Folland ED, Hartigan P; Veterans Affairs ACME Investigators. A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. N Engl J Med. 1992;326:10-16.
33. Pitt B, Waters D, Brown WV, van Boven AJ, Schwartz L, Title LM, Eisenberg D, Shurzinske L, McCormick LS; Atorvastatin versus Revascularization Treatment Investigators. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med. 1999;341:70-76. (Pubitemid 29314237)
34. Zeymer U, Uebis R, Vogt A, Glunz HG, Vöhringer HF, Harmjanz D, Neuhaus KL; ALKK Study Group. Randomized comparison of percutaneous transluminal coronary angioplasty and medical therapy in stable survivors of acute myocardial infarction with single vessel disease: a study of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte. Circulation. 2003;108:1324-1328. (Pubitemid 37174409)
35. Thygesen K, Alpert JS, White HD; Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. J Am Coll Cardiol. 2007;50:2173-2195.
36. Cantor WJ, Newby LK, Christenson RH, Tuttle RH, Hasselblad V, Armstrong PW, Moliterno DJ, Califf RM, Topol EJ, Ohman EM; SYMPHONY and 2nd SYMPHONY Cardiac Markers Substudy Investigators. Prognostic significance of elevated troponin I after percutaneous coronary intervention. J Am Coll Cardiol. 2002;39:1738-1744. (Pubitemid 34595282)
37. Prasad A, Singh M, Lerman A, Lennon RJ, Holmes DR Jr, Rihal CS. Isolated elevation in troponin T after percutaneous coronary intervention is associated with higher long-term mortality. J Am Coll Cardiol. 2006;48:1765-1770. (Pubitemid 44648624)
38. Prasad A, Rihal CS, Lennon RJ, Singh M, Jaffe AS, Holmes DR Jr. Significance of periprocedural myonecrosis on outcomes after percutaneous coronary intervention: an analysis of preintervention and postintervention troponin T levels in 5487 patients. Circ Cardiovasc Interv. 2008;1:10-19.
39. Cavallini C, Savonitto S, Violini R, Arraiz G, Plebani M, Olivari Z, Rubartelli P, Battaglia S, Niccoli L, Steffenino G, Ardissino D; Italian 'Atherosclerosis, Thorombosis, and Vascular Biology' and 'Society for Invasive Cardiology-GISE' Investigators. Impact of the elevation of biochemical markers of myocardial damage on long-term mortality after percutaneous coronary intervention: results of the CK-MB and PCI study. Eur Heart J. 2005;26:1494-1498. (Pubitemid 41373489)
40. Mehran R, Pocock SJ, Stone GW, Clayton TC, Dangas GD, Feit F, Manoukian SV, Nikolsky E, Lansky AJ, Kirtane A, White HD, Colombo A, Ware JH, Moses JW, Ohman EM. Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. Eur Heart J. 2009;30:1457-1466.
41. Hannan EL, Samadashvili Z, Cozzens K, Walford G, Jacobs AK, Holmes DR Jr, Stamato NJ, Gold JP, Sharma S, Venditti FJ, Powell T, King SB III. Comparative outcomes for patients who do and do not undergo percutaneous coronary intervention for stable coronary artery disease in New York. Circulation. 2012;125:1870-1879.
42. Wang TY, Peterson ED, Dai D, Anderson HV, Rao SV, Brindis RG, Roe MT; National Cardiovascular Data Registry. Patterns of cardiac marker surveillance after elective percutaneous coronary intervention and implications for the use of periprocedural myocardial infarction as a quality metric: a report from the National Cardiovascular Data Registry (NCDR). J Am Coll Cardiol. 2008;51:2068-2074. (Pubitemid 351680519)
43. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Katus HA, Lindahl B, Morrow DA, Clemmensen PM, Johanson P, Hod H, Underwood R, Bax JJ, Bonow RO, Pinto F, Gibbons RJ, Fox KA, Atar D, Newby LK, Galvani M, Hamm CW, Uretsky BF, Steg PG, Wijns W, Bassand JP, Menasché P, Ravkilde J, Ohman EM, Antman EM, Wallentin LC, Armstrong PW, Simoons ML, Januzzi JL, Nieminen MS, Gheorghiade M, Filippatos G, Luepker RV, Fortmann SP, Rosamond WD, Levy D, Wood D, Smith SC, Hu D, Lopez-Sendon JL, Robertson RM, Weaver D, Tendera M, Bove AA, Parkhomenko AN, Vasilieva EJ, Mendis S; Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction. Third universal definition of myocardial infarction. Circulation. 2012;126:2020-2035.
44. International study of comparative health effectiveness with medical and invasive approaches (ISCHEMIA). https://www.Ischemiatrial.org. Accessed August 15, 2012.
45. Palmerini T, Biondi-Zoccai G, Della Riva D, Stettler C, Sangiorgi D, D'Ascenzo F, Kimura T, Briguori C, Sabatè M, Kim HS, De Waha A, Kedhi E, Smits PC, Kaiser C, Sardella G, Marullo A, Kirtane AJ, Leon MB, Stone GW. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet. 2012;379:1393-1402.
46. Chen MS, John JM, Chew DP, Lee DS, Ellis SG, Bhatt DL. Bare metal stent restenosis is not a benign clinical entity. Am Heart J. 2006;151:1260-1264. (Pubitemid 43866610)
47. Bainey KR, Norris CM, Graham MM, Ghali WA, Knudtson ML, Welsh RC; APPROACH Investigators. Clinical in-stent restenosis with bare metal stents: is it truly a benign phenomenon Int J Cardiol. 2008;128:378-382.
48. Bangalore S, Kumar S, Fusaro M, Amoroso N, Attubato MJ, Feit F, Bhatt DL, Slater J. Short-and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. Circulation. 2012;125:2873-2891.
49. De Bruyne B, Pijls NH, Kalesan B, Barbato E, Tonino PA, Piroth Z, Jagic N, Möbius-Winkler S, Mobius-Winckler S, Rioufol G, Witt N, Kala P, MacCarthy P, Engström T, Oldroyd KG, Mavromatis K, Manoharan G, Verlee P, Frobert O, Curzen N, Johnson JB, Jüni P, Fearon WF; FAME 2 Trial Investigators. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med. 2012;367:991-1001.